The effects of ghrelin and LEAP-2 in energy homeostasis are modulated by thermoneutrality, high-fat diet and aging
Journal of Endocrinological Investigation · 2024
DOI: 10.1007/s40618-024-02307-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, 2024. Verfasst von S Casado und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Fisioloxía and Centro de Investigación en Medicina Molecular (CIMUS), Universidade de Santiago de Compostela, Instituto de Investigac…. Hauptthemen laut MEDLINE: Ghrelin, Diet, High-Fat, Energy Metabolism, Homeostasis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Economía y Competitividad, Xunta de Galicia, Centro de Investigación Biomédica en Red Obesidad (CIBEROBN).
Abstract (Originalsprache)
Purpose
Liver-expressed antimicrobial peptide 2 (LEAP-2) has been recently identified as the endogenous non-competitive allosteric antagonist of the growth hormone secretagogue receptor 1a (GHSR1a). In rodents, LEAP-2 blunts ghrelin-induced feeding and its plasma levels are modulated in response to nutritional status, being decreased upon fasting and increased in high-fat diet (HFD) fed mice. Clinical data support the regulation of circulating LEAP-2 by nutrient availability in humans. In this work, our primary objective was to examine the chronic effects of ghrelin and LEAP-2 administration on food intake, adiposity, and energy expenditure in young mice subjected to standard and HFD at both room temperature and at thermoneutrality. Furthermore, we aimed to assess the impact of these two hormones on aging mice.
Results
Our results indicate that LEAP-2 produces a significant decrease of body weight and adiposity, an increase in energy expenditure, and activation of the thermogenic program in white and brown adipose tissue depots. However, this effect is not maintained under HFD or under thermoneutral conditions and is only partially observed in aging mice.
Conclusion
In summary our studies describe the central effects of LEAP-2 within distinct experimental contexts, and contribute to the comprehension of LEAP-2's role in energy metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Fisioloxía and Centro de Investigación en Medicina Molecular (CIMUS), Universidade de Santiago de Compostela, Instituto de Investigaciones Sanitarias de Santiago de Compostela (IDIS), 15782, Santiago de…
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain.
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain. carlos.dieguez@usc.es.
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain. sulay.tovar@usc.es.
Förderung
- Ministerio de Economía y Competitividad
- Xunta de Galicia
- Centro de Investigación Biomédica en Red Obesidad (CIBEROBN)
- Universidade de Santiago de Compostela
Zitieren
APA
Casado, S., Varela-Miguéns, M., de Oliveira Diz, T., Quintela-Vilariño, C., Nogueiras, R., Diéguez, C., & Tovar, S. (2024). The effects of ghrelin and LEAP-2 in energy homeostasis are modulated by thermoneutrality, high-fat diet and aging. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02307-4
Vancouver
Casado S, Varela-Miguéns M, de Oliveira Diz T, Quintela-Vilariño C, Nogueiras R, Diéguez C, et al. The effects of ghrelin and LEAP-2 in energy homeostasis are modulated by thermoneutrality, high-fat diet and aging. Journal of Endocrinological Investigation. 2024. doi:10.1007/s40618-024-02307-4
BibTeX
@article{Casado2024,
author = {Casado, S and Varela-Miguéns, M and de Oliveira Diz, T and Quintela-Vilariño, C and Nogueiras, R and Diéguez, C and Tovar, S},
title = {The effects of ghrelin and LEAP-2 in energy homeostasis are modulated by thermoneutrality, high-fat diet and aging},
journal = {Journal of Endocrinological Investigation},
year = {2024},
doi = {10.1007/s40618-024-02307-4}
}
EUVIMED